The cost-effectiveness of repeat HIV testing during pregnancy in a resource-limited setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages 195-200

  Kim, Lena H ^a   Cohan, Deborah L ^a   Sparks, Teresa N ^b   Pilliod, Rachel A ^b   Arinaitwe, Emmanuel ^c   Caughey, Aaron B ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cost effectiveness analysis; Decision analysis; HIV; Perinatal transmission; Pregnancy

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEVIRAPINE; VIRUS RNA;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; GROSS NATIONAL PRODUCT; HEALTH SERVICE; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; PREGNANCY; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; REPEAT PROCEDURE; UGANDA; VERTICAL TRANSMISSION; VIRUS DETECTION; WORLD HEALTH ORGANIZATION; BLOOD; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE TRANSMISSION; ECONOMICS; GENETICS; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MASS SCREENING; PREGNANCY COMPLICATION; QUALITY ADJUSTED LIFE YEAR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH RESOURCES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; QUALITY-ADJUSTED LIFE YEARS; RNA, VIRAL; UGANDA;

MLCS; MLOWN;

EID: 84879741319     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182895565     Document Type: Article

References (30)

1. World Health Organization/UNAIDS. AIDS epidemic update: December 2009. In: Joint United Nations Programme on HIV/AIDS and World Health Organization. Geneva, Switzerland: WHO and UNAIDS; 2009.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
3. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175-1182.
4. Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet. 2005;366: 1182-1188.
5. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189: 1785-1792.
6. Keating MA, Hamela G, Miller WC, et al. High HIV incidence and sexual behavior change among pregnant women in Lilongwe, Malawi: implications for the risk of HIV acquisition. PLoS One. 2012;7:e39109.
7. Ugandan Ministry of Health. Ministry of Health, Republic of Uganda: Uganda Clinical Guidelines 2010, National Guidelines on Common Conditions. Kampala, Uganda: Ugandan Ministry of Health. 2010.
8. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16: 1119-1129.
9. Lelie PN, van Drimmelen HA, Cuypers HT, et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion. 2002; 42:527-536.
10. Moodley D, Esterhuizen TM, Pather T, et al. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS. 2009;23: 1255-1259.
11. Morrison CS, Wang J, Van Der Pol B, et al. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS. 2007;21:1027-1034.
12. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
13. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
14. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet. 2007;369:1107-1116.
15. Liang K, Gui X, Zhang YZ, et al. A case series of 104 women infected with HIV-1 via blood transfusion postnatally: high rate of HIV-1 transmission to infants through breast-feeding. J Infect Dis. 2009;200:682-686.
16. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52:406-416.
17. Wilkinson D, Wilkinson N, Lombard C, et al. On-site HIV testing in resource-poor settings: is one rapid test enough? AIDS. 1997;11:377-381.
18. WHO, UNICEF, UNAIDS & MSF. Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS. A Joint UNICEF-UNAIDS-WHO-MSF Project. Available at: http://www.unicef.org/supply/index-8362.html. Accessed April 5, 2013.
19. Rely K, Bertozzi SM, Avila-Figueroa C, et al. Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting. Health Policy Plan. 2003;18:290-298.
20. UNAIDS. 2008 Report on the global AIDS epidemic: Joint United Nations Programme on HIV/AIDS. Geneva, Switzerland: UNAIDS; 2008.
21. Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med. 2006; 3:e517.
22. van Sighem AI, Gras LA, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of unin-fected individuals. AIDS. 2010;24:1527-1535.
23. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
24. WHO. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recomendations for a Public Health Approach, 2010 version. Geneva, Switzerland: World Health Organization; 2010.
25. Cardiello PG, van Heeswijk RP, Hassink EA, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr. 2002;29:464-470.
26. Bentsen C, McLaughlin L, Mitchell E, et al. Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma. J Clin Virol. 2011;52(suppl 1):S57-S61.
27. Mayhood MK, Afwamba IA, Odhiambo CO, et al. Validation, performance under field conditions, and cost-effectiveness of Capillus HIV-1/HIV-2 and determine HIV-1/2 rapid human immunodeficiency virus antibody assays using sequential and parallel testing algorithms in Tanzania. J Clin Micro-biol. 2008;46:3946-3951.
28. Khamadi S, Okoth V, Lihana R, et al. Rapid identification of infants for antiretroviral therapy in a resource poor setting: the Kenya experience. J Trop Pediatr. 2008;54:370-374.
29. Glynn JR, Sonnenberg P, Nelson G, et al. Survival from HIV-1 serocon-version in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 2007;21:625-632.
30. WHO. Uganda: Summary Country Profile for HIV/AIDS Treatment Scale-up. Geneva, Switzerland: World Health Organization; 2005. Available at: www.who.int/3by5/june2005-uga.pdf. Accessed April 5, 2013.